Valerio Therapeutics Société anonyme (ALVIO.PA)
EUR 0.08
(3.31%)
EUR 0.08
(3.31%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -18.91 Million EUR | -8.72% |
| 2022 | -17.03 Million EUR | -248.92% |
| 2021 | -4.89 Million EUR | 40.14% |
| 2020 | 2.33 Million EUR | -210.92% |
| 2019 | -35.66 Million EUR | 878.67% |
| 2018 | -946 Thousand EUR | 96.29% |
| 2017 | -67.56 Million EUR | -28.74% |
| 2016 | -19.78 Million EUR | -8.87% |
| 2015 | -19.5 Million EUR | -627.89% |
| 2014 | -1.33 Million EUR | 123.28% |
| 2013 | -15.18 Million EUR | -36.38% |
| 2012 | -10.85 Million EUR | 21.22% |
| 2011 | -14.42 Million EUR | -492.41% |
| 2010 | 3.33 Million EUR | 124.11% |
| 2009 | -14.76 Million EUR | 30.15% |
| 2008 | -20.84 Million EUR | -18.67% |
| 2007 | -18.04 Million EUR | -31.13% |
| 2006 | -13.02 Million EUR | -101.68% |
| 2005 | -6.64 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -4.71 Million EUR | -29.81% |
| 2024 Q2 | -4.71 Million EUR | 0.0% |
| 2023 Q2 | -12.22 Million EUR | -111.47% |
| 2023 Q3 | -3.63 Million EUR | 70.29% |
| 2023 Q4 | -3.63 Million EUR | 0.0% |
| 2023 FY | - EUR | -8.72% |
| 2023 Q1 | -5.77 Million EUR | 37.08% |
| 2022 FY | - EUR | -248.92% |
| 2022 Q2 | -9.58 Million EUR | -114.98% |
| 2022 Q3 | -4.06 Million EUR | 57.63% |
| 2022 Q4 | -9.18 Million EUR | -126.2% |
| 2022 Q1 | -4.45 Million EUR | -118.32% |
| 2021 Q2 | -4.77 Million EUR | -132.37% |
| 2021 Q4 | -2.04 Million EUR | -493.6% |
| 2021 FY | - EUR | 40.14% |
| 2021 Q1 | -2.05 Million EUR | 49.38% |
| 2021 Q3 | -344 Thousand EUR | 92.79% |
| 2020 FY | - EUR | -210.92% |
| 2020 Q3 | 2.7 Million EUR | 163.83% |
| 2020 Q4 | -4.05 Million EUR | -250.08% |
| 2020 Q2 | -4.23 Million EUR | -120.99% |
| 2020 Q1 | -1.91 Million EUR | 36.91% |
| 2019 Q3 | -1.21 Million EUR | 83.69% |
| 2019 Q4 | -3.03 Million EUR | -150.43% |
| 2019 Q2 | -7.43 Million EUR | -129.64% |
| 2019 FY | - EUR | 878.67% |
| 2019 Q1 | -3.23 Million EUR | 35.84% |
| 2018 Q1 | -2.58 Million EUR | 26.04% |
| 2018 FY | - EUR | 96.29% |
| 2018 Q4 | -5.04 Million EUR | 0.0% |
| 2018 Q3 | -5.04 Million EUR | -95.43% |
| 2018 Q2 | -2.58 Million EUR | 0.0% |
| 2017 Q4 | -3.49 Million EUR | 0.0% |
| 2017 FY | - EUR | -28.74% |
| 2017 Q1 | -5.2 Million EUR | 5.82% |
| 2017 Q2 | -5.2 Million EUR | 0.0% |
| 2017 Q3 | -3.49 Million EUR | 32.89% |
| 2016 Q3 | -5.52 Million EUR | -7.79% |
| 2016 FY | - EUR | -8.87% |
| 2016 Q1 | -5.12 Million EUR | -8.46% |
| 2016 Q2 | -5.12 Million EUR | 0.0% |
| 2016 Q4 | -5.52 Million EUR | 0.0% |
| 2015 Q1 | -5.53 Million EUR | -222.88% |
| 2015 Q2 | -5.53 Million EUR | 0.0% |
| 2015 FY | - EUR | -627.89% |
| 2015 Q4 | -4.72 Million EUR | 0.0% |
| 2015 Q3 | -4.72 Million EUR | 14.57% |
| 2014 Q1 | -4.2 Million EUR | -8.84% |
| 2014 FY | - EUR | 123.28% |
| 2014 Q3 | 4.5 Million EUR | 206.95% |
| 2014 Q2 | -4.2 Million EUR | 0.0% |
| 2014 Q4 | 4.5 Million EUR | 0.0% |
| 2013 FY | - EUR | -36.38% |
| 2013 Q2 | -3.72 Million EUR | 0.0% |
| 2013 Q1 | -3.72 Million EUR | 0.0% |
| 2013 Q3 | -3.86 Million EUR | -3.78% |
| 2013 Q4 | -3.86 Million EUR | 0.0% |
| 2012 FY | - EUR | 21.22% |
| 2011 FY | - EUR | -492.41% |
| 2010 FY | - EUR | 124.11% |
| 2009 FY | - EUR | 30.15% |
| 2008 FY | - EUR | -18.67% |
| 2007 FY | - EUR | -31.13% |
| 2006 FY | - EUR | -101.68% |
| 2005 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -474.954% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 85.8% |
| Adocia SA | -22.73 Million EUR | 16.787% |
| Aelis Farma SA | -6.34 Million EUR | -198.031% |
| Biophytis S.A. | -13.8 Million EUR | -37.033% |
| Advicenne S.A. | -6.24 Million EUR | -202.947% |
| genOway Société anonyme | 6.35 Million EUR | 397.855% |
| IntegraGen SA | -52.5 Thousand EUR | -35928.417% |
| Medesis Pharma S.A. | -3.84 Million EUR | -391.978% |
| Neovacs S.A. | -8.44 Million EUR | -123.87% |
| NFL Biosciences SA | -4.04 Million EUR | -367.142% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 26180.243% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -558.296% |
| Sensorion SA | -22.31 Million EUR | 15.227% |
| Theranexus Société Anonyme | -7.38 Million EUR | -156.063% |
| TME Pharma N.V. | -5.07 Million EUR | -272.95% |
| Valbiotis SA | -6.95 Million EUR | -171.977% |
| TheraVet SA | -517.33 Thousand EUR | -3556.424% |
| argenx SE | -199.5 Million EUR | 90.519% |
| BioSenic S.A. | -6.79 Million EUR | -178.34% |
| Celyad Oncology SA | -7.76 Million EUR | -143.669% |
| DBV Technologies S.A. | -79.53 Million EUR | 76.216% |
| Galapagos NV | 51.03 Million EUR | 137.063% |
| Genfit S.A. | -28.05 Million EUR | 32.566% |
| GeNeuro SA | -14.31 Million EUR | -32.116% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -26.275% |
| Innate Pharma S.A. | -7.57 Million EUR | -149.617% |
| Inventiva S.A. | -101.84 Million EUR | 81.427% |
| MaaT Pharma SA | -19.74 Million EUR | 4.174% |
| MedinCell S.A. | -20.04 Million EUR | 5.637% |
| Nanobiotix S.A. | -34.01 Million EUR | 44.396% |
| Onward Medical N.V. | -35.23 Million EUR | 46.313% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -326.674% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 18.697% |
| Oxurion NV | -16.72 Million EUR | -13.073% |
| Pharming Group N.V. | 4.98 Million EUR | 479.766% |
| Poxel S.A. | -12.17 Million EUR | -55.317% |
| GenSight Biologics S.A. | -21.73 Million EUR | 12.95% |
| Transgene SA | -27.02 Million EUR | 30.003% |
| Financière de Tubize SA | 184.57 Thousand EUR | 10348.631% |
| UCB SA | 1.26 Billion EUR | 101.491% |
| Valneva SE | -64.51 Million EUR | 70.681% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 33.284% |